Search Results - "Gamazon, E.R"

A Coding Polymorphism in PFAS (The Gene Encoding Phosphoribosylformylglycinamidine Synthase) Is a Determinant of Prostacyclin Dose by Thomeas, V, Maitland, M.L, Benza, R.L, Tamari, M, Gamazon, E.R, Konkashbaev, A, Wheeler, H, Hirota, T, Kubo, M, Cox, N.J, Gomberg-Maitland, M

Get full text

Two Polymorphic Gene Loci Associated with Treprostinil Dose in Pulmonary Arterial Hypertension by Psotka, M.A., Thomeas-McEwing, V., Gamazon, E.R., Hirota, T., Friedman, P.N., Konkashbaev, A., Kubo, M., Nakamura, Y., Ratain, M.J., Benza, R.L., Cox, N.J., Gomberg-Maitland, M.I., Maitland, M.L.

“…Prostacyclin infusion is an effective therapy for pulmonary arterial hypertension (PAH) but has variable clinical response and dosing requirements. We…”
Get full text

Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans by Hernandez, W, Gamazon, E R, Aquino-Michaels, K, Patel, S, O'Brien, T J, Harralson, A F, Kittles, R A, Barbour, A, Tuck, M, McIntosh, S D, Douglas, J N, Nicolae, D, Cavallari, L H, Perera, M A

“…Using a derivation cohort ( N =349), we developed the first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9…”
Get full text

Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans by Hernandez, W., Gamazon, E. R., Aquino‐Michaels, K., Smithberger, E., O'Brien, T. J., Harralson, A. F., Tuck, M., Barbour, A., Cavallari, L. H., Perera, M. A.

“…Essentials Genetic variants controlling gene regulation have not been explored in pharmacogenomics. We tested liver expression quantitative trait loci for…”
Get full text

Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children’s Oncology Group by Kutny, M A, Alonzo, T A, Gamazon, E R, Gerbing, R B, Geraghty, D, Lange, B, Heerema, N A, Sung, L, Aplenc, R, Franklin, J, Raimondi, S C, Hirsch, B A, Konkashbaev, A, Cox, N J, Onel, K, Gamis, A S, Meshinchi, S

Get full text

Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations by Wheeler, H E, Gamazon, E R, Stark, A L, O'Donnell, P H, Gorsic, L K, Huang, R S, Cox, N J, Dolan, M E

“…Platinating agents are used in the treatment of many cancers, yet they can induce toxicities and resistance that limit their utility. Using previously…”
Get full text

Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation by Weng, L., Ziliak, D., Im, H.K., Gamazon, E.R., Philips, S., Nguyen, A.T., Desta, Z., Skaar, T.C., Flockhart, D.A., Huang, R.S.

“…Beyond estrogen receptor (ER), there are no validated predictors for tamoxifen (TAM) efficacy and toxicity. We utilized a genome-wide cell-based model to…”
Get full text